Compare MSLE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSLE | EQ |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | 17 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 129.0M |
| IPO Year | N/A | 2018 |
| Metric | MSLE | EQ |
|---|---|---|
| Price | $6.71 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 29.4K | ★ 248.2K |
| Earning Date | N/A | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $0.29 |
| 52 Week High | $13.39 | $2.70 |
| Indicator | MSLE | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 63.26 |
| Support Level | $6.73 | $1.64 |
| Resistance Level | $8.59 | N/A |
| Average True Range (ATR) | 0.50 | 0.26 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 22.22 | 89.64 |
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.